Investigational drug · Phase 2
Foralumab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Secondary Progressive Multiple Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
12
Any phase or sponsor naming "Foralumab"
First trial start
2023
Nov 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Foralumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Secondary Progressive Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Foralumab" as an intervention, largest first.
Brigham and Women's HospitalAcademic, hospital or other
NCT02649985 · 250 participants (planned) · Start May 2, 2016 · Primary completion Dec 31, 2027
Drug: [F-18]PBR06; [C-11]PBR28 · For: Multiple Sclerosis; Alzheimer's Disease
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT06890923 · 55 participants (planned) · Start Mar 4, 2025 · Primary completion Apr 30, 2026
Drug: Foralumab TZLS-401 100 µg · For: Non-Active Secondary Progressive Multiple Sclerosis
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT06292923 · 54 participants · Start Nov 15, 2023 · Primary completion Sep 17, 2026
Drug: Foralumab · For: Secondary Progressive Multiple Sclerosis
Sites: North Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 8 sites in all
- The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabEnrolling by invitation
Tiziana Life Sciences LTDIndustry
NCT07688239 · 44 participants (planned) · Start Sep 23, 2026 · Primary completion Jul 2027
Drug: Foralumab Nasal; Placebo · For: ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS
Sites: Davie, Florida; Chicago, Illinois; Boston, Massachusetts · 4 sites in all
Tiziana Life Sciences LTDIndustry
NCT06879067 · 27 participants · Start Nov 12, 2018 · Primary completion Jul 23, 2019
Drug: Placebo; Foralumab Nasal · For: Safety; Tolerability
Sites: Boston, Massachusetts
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseaseRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06489548 · 16 participants (planned) · Start Sep 16, 2025 · Primary completion Jun 2026
Drug: Foralumab TZLS-401 50 µg; Foralumab TZLS-401 100 µg · For: Dementia; Alzheimers Disease; Mild Cognitive Impairment Due to Alzheimer's Disease
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT06868628 · 5 participants (planned) · Start May 19, 2025 · Primary completion Apr 1, 2027
Drug: Foralumab Nasal · For: Multiple System Atrophy
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT05028946 · 0 participants · Start May 1, 2022 · Primary completion Jul 7, 2023
Drug: Foralumab · For: Crohn's Disease
Tiziana Life Sciences LTDIndustry
NCT04983446 · 0 participants · Start Apr 30, 2022 · Primary completion Oct 30, 2022
Drug: Foralumab · For: Covid19; COVID-19 Lower Respiratory Infection; COVID-19 Respiratory Infection
- Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DMWithdrawn
Tiziana Life Sciences LTDIndustry
NCT03291249 · 0 participants · Start Dec 1, 2017 · Primary completion Dec 1, 2018
Drug: Foralumab; Omeprazole 20mg · For: NASH - Nonalcoholic Steatohepatitis; NAFLD; T2DM (Type 2 Diabetes Mellitus)
Newest research
PubMed records naming it or its code names, newest first.
- Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions.
Skarlis C, Angelopoulou E, Rentzos M, et al. · Int J Mol Sci 2025
- Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia.
Singhal T, Cicero S, Gale SA, et al. · Clin Nucl Med 2025
- Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS.
Chitnis T, Singhal T, Zurawski J, et al. · medRxiv 2025
- Nasal administration of anti-CD3 mAb (Foralumab) downregulates NKG7 and increases TGFB1 and GIMAP7 expression in T cells in subjects with COVID-19.
G Moreira T, Gauthier CD, Murphy L, et al. · Proc Natl Acad Sci U S A 2023
- Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects.
Chitnis T, Kaskow BJ, Case J, et al. · Front Immunol 2022
- Injection Effect of Anti-CD3 Monoclonal Antibody on Primo Vessel in Lymph Vessel of Rabbit with Lipopolysaccharide-Induced Inflammation.
Choi SH, Choi JG, Lee SS · J Acupunct Meridian Stud 2022
Also in development for Secondary Progressive Multiple Sclerosis
- OrelabrutinibICP-022Phase 311 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies
- TolebrutinibSAR442168Phase 33 trials
Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.